...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Gastroenterology >Development of a novel lipid metabolism-based risk score model in hepatocellular carcinoma patients
【24h】

Development of a novel lipid metabolism-based risk score model in hepatocellular carcinoma patients

机译：肝细胞癌患者中新型脂质代谢的风险评分模型的发展

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Liver cancer is one of the most common malignancies worldwide. HCC (hepatocellular carcinoma) is the predominant pathological type of liver cancer, accounting for approximately 75–85?% of all liver cancers. Lipid metabolic reprogramming has emerged as an important feature of HCC. However, the influence of lipid metabolism-related gene expression in HCC patient prognosis remains unknown. In this study, we performed a comprehensive analysis of HCC gene expression data from TCGA (The Cancer Genome Atlas) to acquire further insight into the role of lipid metabolism-related genes in HCC patient prognosis. We analyzed the mRNA expression profiles of 424 HCC patients from the TCGA database. GSEA(Gene Set Enrichment Analysis) was performed to identify lipid metabolism-related gene sets associated with HCC. We performed univariate Cox regression and LASSO(least absolute shrinkage and selection operator) regression analyses to identify genes with prognostic value and develop a prognostic model, which was tested in a validation cohort. We performed Kaplan-Meier survival and ROC (receiver operating characteristic) analyses to evaluate the performance of the model. We identified three lipid metabolism-related genes (ME1, MED10, MED22) with prognostic value in HCC and used them to calculate a risk score for each HCC patient. High-risk HCC patients exhibited a significantly lower survival rate than low-risk patients. Multivariate Cox regression analysis revealed that the 3-gene signature was an independent prognostic factor in HCC. Furthermore, the signature provided a highly accurate prediction of HCC patient prognosis. We identified three lipid-metabolism-related genes that are upregulated in HCC tissues and established a 3-gene signature-based risk model that can accurately predict HCC patient prognosis. Our findings support the strong links between lipid metabolism and HCC and may facilitate the development of new metabolism-targeted treatment approaches for HCC.
机译：肝癌是全球最常见的恶性肿瘤之一。 HCC（肝细胞癌）是肝癌的主要病理类型，占所有肝癌的75-85〜5〜5〜85粒。脂质代谢重编程已成为HCC的重要特征。然而，脂质代谢相关基因表达在HCC患者预后的影响仍然未知。在这项研究中，我们对来自TCGA（癌症基因组Atlas）的HCC基因表达数据进行了综合分析，以进一步了解脂质代谢相关基因在HCC患者预后的作用。我们分析了来自TCGA数据库424个HCC患者的mRNA表达谱。进行GSEA（基因集富集分析）以鉴定与HCC相关的脂质代谢相关基因集。我们执行了单变量的Cox回归和套索（最小绝对收缩和选择操作员）回归分析以鉴定具有预后值的基因，并开发预后模型，该模型在验证队列中进行了测试。我们执行了Kaplan-Meier生存期和ROC（接收器操作特征）分析以评估模型的性能。我们鉴定了三种脂质代谢相关基因（ME1，MED10，MED22），具有HCC的预后值，并使用它们来计算每个HCC患者的风险得分。高风险HCC患者表现出比低风险患者的存活率明显降低。多变量COX回归分析显示，3-基因签名是HCC的独立预后因素。此外，签名提供了对HCC患者预后的高度准确预测。我们确定了三种脂质代谢相关基因，其在HCC组织中上调，并建立了一种可以准确地预测HCC患者预后的3基因签名的风险模型。我们的研究结果支持脂质代谢和HCC之间的强烈联系，并可促进HCC的新代谢针对性治疗方法的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号